ArticleJournal for immunotherapy of cancer2024

Molecular assessment of intratumoral immune cell subsets and potential mechanisms of resistance to odronextamab, a CD20×CD3 bispecific antibody, in patients with relapsed/refractory B-cell non-Hodgkin lymphoma.

Jurriaan Brouwer-Visser et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.